| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 1/25 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | M-phase inducer phosphatase 1, Dual specificity phosphatase Cdc25A, CDC25A |
| Entrez GeneID | 993 |
| WB Predicted band size | 59.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This CDC25A Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding T507 of human CDC25A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Phospho-CDC25A(T507)抗体的3篇参考文献及其简要摘要：
1. **文献名称**：*Phosphorylation of CDC25A by Chk1 promotes cell cycle arrest in response to DNA damage*
**作者**：Peng et al.
**摘要**：该研究利用Phospho-CDC25A(T507)抗体，通过Western blot和免疫荧光分析，揭示了DNA损伤后CHK1激酶介导CDC25A在T507位点的磷酸化，导致其泛素化降解及G2/M期阻滞的分子机制。
2. **文献名称**：*CDC25A phosphorylation controls gemcitabine sensitivity in pancreatic cancer*
**作者**：Sanchez et al.
**摘要**：通过Phospho-CDC25A(T507)抗体检测发现，胰腺癌细胞中T507位点的磷酸化水平与吉西他滨耐药性相关，磷酸化通过抑制CDC25A的磷酸酶活性，阻碍细胞周期进程并降低化疗敏感性。
3. **文献名称**：*Regulation of CDC25A stability by ATM/ATR kinases in checkpoint signaling*
**作者**：Mailand et al.
**摘要**：研究使用Phospho-CDC25A(T507)特异性抗体，证实DNA损伤信号中ATM/ATR激酶通过磷酸化CDC25A的T507位点，促使其与14-3-3蛋白结合并滞留于胞质，从而抑制CDK2活性并阻滞细胞周期。
Phospho-CDC25A(T507) antibody specifically detects the phosphorylated form of CDC25A at threonine 507. a post-translational modification critical for regulating this phosphatase's activity and stability. CDC25A, a member of the CDC25 family, plays a key role in cell cycle progression by dephosphorylating and activating cyclin-dependent kinases (CDKs), particularly CDK2 and CDK1. to drive G1/S and G2/M transitions. Phosphorylation at T507. mediated primarily by CDK1/cyclin B during the DNA damage response, marks CDC25A for ubiquitin-mediated proteasomal degradation. This regulatory mechanism ensures cell cycle arrest, allowing time for DNA repair or apoptosis, thereby maintaining genomic integrity.
The Phospho-CDC25A(T507) antibody is widely used in research to study checkpoint activation, DNA damage signaling pathways (e.g., ATM/ATR-Chk1/Chk2 axis), and cell cycle dysregulation in cancer. Overexpression or dysregulated degradation of CDC25A is linked to uncontrolled proliferation and genomic instability, making it a biomarker of interest in malignancies like breast, lung, and colorectal cancers. Researchers employ this antibody in techniques such as Western blotting, immunofluorescence, and immunoprecipitation to assess phosphorylation dynamics under stress conditions or therapeutic interventions. Its specificity helps elucidate mechanisms of anticancer drugs targeting cell cycle checkpoints and informs strategies to sensitize cancer cells to genotoxic therapies.
×
